GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (LTS:0ACX) » Definitions » Equity-to-Asset

Centessa Pharmaceuticals (LTS:0ACX) Equity-to-Asset : 0.82 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Centessa Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Centessa Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $499.14 Mil. Centessa Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $609.72 Mil.

The historical rank and industry rank for Centessa Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

LTS:0ACX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.91   Med: 0.77   Max: 0.91
Current: 0.82

During the past 5 years, the highest Equity to Asset Ratio of Centessa Pharmaceuticals was 0.91. The lowest was -1.91. And the median was 0.77.

LTS:0ACX's Equity-to-Asset is ranked better than
69.58% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs LTS:0ACX: 0.82

Centessa Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Centessa Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Equity-to-Asset Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
- -1.91 0.78 0.76 0.66

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.66 0.66 0.72 0.82

Competitive Comparison of Centessa Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Centessa Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Equity-to-Asset falls into.



Centessa Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Centessa Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=236.244/360.246
=0.66

Centessa Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=499.137/609.715
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (LTS:0ACX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Centessa Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals Business Description

Comparable Companies
Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals Headlines

No Headlines